ES2194480T3 - Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. - Google Patents

Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.

Info

Publication number
ES2194480T3
ES2194480T3 ES99931261T ES99931261T ES2194480T3 ES 2194480 T3 ES2194480 T3 ES 2194480T3 ES 99931261 T ES99931261 T ES 99931261T ES 99931261 T ES99931261 T ES 99931261T ES 2194480 T3 ES2194480 T3 ES 2194480T3
Authority
ES
Spain
Prior art keywords
preparation
coating
procedure
oral pharmaceutical
activity compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99931261T
Other languages
English (en)
Inventor
Darder Carlos Picornell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratorios Liconsa SA
Original Assignee
Liconsa Liberacion Controlada de Sustancias Activas SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8304581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2194480(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liconsa Liberacion Controlada de Sustancias Activas SA filed Critical Liconsa Liberacion Controlada de Sustancias Activas SA
Application granted granted Critical
Publication of ES2194480T3 publication Critical patent/ES2194480T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Comprende un compuesto de actividad antifúngica como principio activo, un núcleo inerte y un recubrimiento que incluye dicho principio activo, y se caracteriza por el hecho de que dicho núcleo inerte presenta un tamaño de partícula comprendido entre 50-600 µm, y por el hecho de que dicho recubrimiento comprende una única capa que se obtiene por nebulización, sobre dicho núcleo inerte, de una solución que comprende un compuesto de actividad antifúngica, un polímero hidrofílico y un agente tensioactivo no iónico. El procedimiento se lleva a cabo mediante un recubrimiento que comprende una única capa de los núcleos inertes de tamaño entre 50 y 600 µm por nebulización de una solución compuesta por el agente antifúngico, el polímero hidrofílico y el agente tensioactivo no iónico a una velocidad de recubrimiento constante durante todo el proceso; y un solo secado de dicho recubrimiento en el mismo equipo.
ES99931261T 1998-07-21 1999-07-20 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. Expired - Lifetime ES2194480T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801539A ES2157731B1 (es) 1998-07-21 1998-07-21 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.

Publications (1)

Publication Number Publication Date
ES2194480T3 true ES2194480T3 (es) 2003-11-16

Family

ID=8304581

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801539A Expired - Fee Related ES2157731B1 (es) 1998-07-21 1998-07-21 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
ES99931261T Expired - Lifetime ES2194480T3 (es) 1998-07-21 1999-07-20 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES009801539A Expired - Fee Related ES2157731B1 (es) 1998-07-21 1998-07-21 Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.

Country Status (31)

Country Link
US (1) US6737082B1 (es)
EP (1) EP1103252B1 (es)
JP (1) JP4190732B2 (es)
KR (1) KR100572135B1 (es)
AT (1) ATE234077T1 (es)
AU (1) AU750730B2 (es)
BG (1) BG65187B1 (es)
BR (1) BR9912300A (es)
CA (1) CA2337509C (es)
CZ (1) CZ291938B6 (es)
DE (1) DE69905905T2 (es)
DK (1) DK1103252T3 (es)
EE (1) EE04415B1 (es)
ES (2) ES2157731B1 (es)
HK (1) HK1037531A1 (es)
HR (1) HRP20010128B1 (es)
HU (1) HU228895B1 (es)
IL (1) IL140910A (es)
ME (1) MEP26708A (es)
MX (1) MXPA01000681A (es)
NO (1) NO320054B1 (es)
NZ (1) NZ509886A (es)
PL (1) PL194740B1 (es)
PT (1) PT1103252E (es)
RS (1) RS50063B (es)
RU (1) RU2209628C2 (es)
SK (1) SK283279B6 (es)
TR (1) TR200100177T2 (es)
UA (1) UA64009C2 (es)
WO (1) WO2000004881A1 (es)
ZA (1) ZA200101293B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243981C (en) * 1996-01-31 2005-09-06 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
ES2283724T5 (es) * 2003-01-14 2013-04-09 Acino Pharma Ag Composición de itraconazol dispersada en un polímero hidrófilo con biodisponibilidad potenciada
DE60312636T3 (de) * 2003-01-14 2014-12-24 Acino Pharma Ag Bioaequivalente Zusammensetzung in der Form einer festen Dispersion enthaltend Itraconazol und ein hydrophiles Polymer
FR2852607B1 (fr) * 2003-03-20 2006-07-14 Procede de fabrication de microspheres de sucre de petite taille, les microspheres susceptibles d'etre obtenues par ce procede et leurs applications
ES2667668T3 (es) * 2003-07-17 2018-05-14 Janssen Sciences Ireland Uc Procedimiento para preparar partículas que contienen un antiviral
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
EP1919480B1 (en) 2005-08-22 2013-01-16 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
CN101283984B (zh) * 2007-04-12 2010-05-26 永胜药品工业股份有限公司 高生物使用率的经杀真菌剂和聚合物涂覆的核心微粒状物
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2542222A2 (de) * 2010-03-05 2013-01-09 Basf Se Schmelzüberzogene arzneiformen
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
AU2016268489A1 (en) * 2015-05-25 2017-12-14 Sun Pharmaceutical Industries Limited Once daily oral pharmaceutical composition of isotretinoin
WO2018031935A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3720844A4 (en) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation MEDICINAL COMPOSITIONS
CN112313289A (zh) * 2018-04-27 2021-02-02 凸版印刷株式会社 缓释性复合颗粒、缓释性复合颗粒的制造方法、干燥粉体、以及壁纸
WO2023118082A1 (en) * 2021-12-22 2023-06-29 Palau Pharma, S.L.U. Multiparticulate albaconazole composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
EP0904060B1 (en) * 1996-05-20 2003-12-10 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
EP0914127B1 (en) * 1996-05-24 2002-02-27 Schering Corporation Antifungal composition with enhanced bioavailability
WO1998000116A1 (en) * 1996-06-28 1998-01-08 Schering Corporation Oral composition comprising a triazole antifungal compound
DE19626924C2 (de) * 1996-07-04 1999-08-19 Epazon B V Gerät zur Bereitstellung eines Atemgases
SI0969821T1 (en) 1997-03-26 2003-10-31 Janssen Pharmaceutica N.V. Pellets having a core coated with an antifungal and a polymer

Also Published As

Publication number Publication date
DE69905905D1 (de) 2003-04-17
ES2157731A1 (es) 2001-08-16
DE69905905T2 (de) 2004-03-04
NO20010289L (no) 2001-03-07
CA2337509C (en) 2005-12-27
PL194740B1 (pl) 2007-06-29
CZ2001175A3 (en) 2001-05-16
SK862001A3 (en) 2001-08-06
CZ291938B6 (cs) 2003-06-18
HK1037531A1 (en) 2002-02-15
CA2337509A1 (en) 2000-02-03
ZA200101293B (en) 2001-08-21
TR200100177T2 (tr) 2001-07-23
EP1103252B1 (en) 2003-03-12
BG105282A (en) 2001-11-30
HUP0103708A3 (en) 2002-07-29
EE200100041A (et) 2002-06-17
MXPA01000681A (es) 2002-04-24
IL140910A0 (en) 2002-02-10
KR100572135B1 (ko) 2006-04-19
YU3901A (sh) 2003-08-29
NZ509886A (en) 2002-09-27
AU4782199A (en) 2000-02-14
IL140910A (en) 2004-03-28
EE04415B1 (et) 2005-02-15
BR9912300A (pt) 2001-04-17
HUP0103708A2 (hu) 2002-02-28
JP4190732B2 (ja) 2008-12-03
RS50063B (sr) 2009-01-22
ES2157731B1 (es) 2002-05-01
PT1103252E (pt) 2003-07-31
PL345625A1 (en) 2002-01-02
WO2000004881A1 (es) 2000-02-03
JP2002521323A (ja) 2002-07-16
BG65187B1 (bg) 2007-06-29
RU2209628C2 (ru) 2003-08-10
EP1103252A1 (en) 2001-05-30
HU228895B1 (en) 2013-06-28
UA64009C2 (en) 2004-02-16
AU750730B2 (en) 2002-07-25
NO20010289D0 (no) 2001-01-17
HRP20010128B1 (en) 2003-12-31
DK1103252T3 (da) 2003-07-14
MEP26708A (en) 2010-06-10
US6737082B1 (en) 2004-05-18
KR20010070990A (ko) 2001-07-28
HRP20010128A2 (en) 2002-12-31
NO320054B1 (no) 2005-10-17
SK283279B6 (sk) 2003-05-02
ATE234077T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
ES2194480T3 (es) Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
CA2396152A1 (en) Osmotic device within an osmotic device
DK1183014T3 (da) Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse
CA2446712A1 (en) System for osmotic delivery of pharmaceutically active agents
IS4328A (is) Fjöleininga lyfjablanda sem inniheldur prótónupumpublokkara
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
JP2003512395A5 (es)
CA2322875A1 (en) A coated chewing gum, a method for preparation thereof and the use of one or more active substance(s) in solid form
DE69523587D1 (de) Fluticasonpropionat-formulierungen
IL149573A0 (en) Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients
FR2774288B1 (fr) Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
AR019745A1 (es) Dispersion de fragancias
AR033862A1 (es) Formulacion de medicamento que contiene un agente agonista muscarinico
RU2002133953A (ru) Способ лечения больных генерализованным пародонтитом
UY26503A1 (es) " forma de dosificación de fármacos accionada por un hidrogel"
RU99118348A (ru) Средство для подавления роста сульфатвосстанавливающих бактерий